BSE Live
Mar 16, 16:01Prev. Close
370.10
Open Price
369.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 16, 15:59Prev. Close
368.75
Open Price
370.00
Bid Price (Qty.)
366.15 (100)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of SMS Pharmaceuticals (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 41.63 | 23.06 | 25.29 | 1.14 | 8.38 | |
| Diluted EPS (Rs.) | 41.63 | 23.06 | 25.29 | 1.14 | 8.38 | |
| Cash EPS (Rs.) | 61.91 | 39.27 | 38.99 | 13.76 | 21.00 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 300.95 | 262.02 | 243.69 | 220.75 | 219.61 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 300.95 | 262.02 | 243.69 | 220.75 | 219.61 | |
| Dividend / Share(Rs.) | 2.00 | 2.00 | 2.00 | 0.00 | 1.50 | |
| Revenue from Operations/Share (Rs.) | 684.31 | 611.96 | 241.96 | 213.77 | 225.60 | |
| PBDIT/Share (Rs.) | 121.18 | 69.33 | -34.41 | 38.12 | 40.94 | |
| PBIT/Share (Rs.) | 100.90 | 54.15 | -48.11 | 25.50 | 28.31 | |
| PBT/Share (Rs.) | 79.72 | 37.82 | -72.34 | 1.42 | 10.47 | |
| Net Profit/Share (Rs.) | 41.63 | 24.08 | 25.29 | 1.14 | 8.38 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 17.70 | 11.32 | -14.22 | 17.83 | 18.14 | |
| PBIT Margin (%) | 14.74 | 8.84 | -19.88 | 11.92 | 12.54 | |
| PBT Margin (%) | 11.64 | 6.18 | -29.89 | 0.66 | 4.64 | |
| Net Profit Margin (%) | 6.08 | 3.93 | 10.45 | 0.53 | 3.71 | |
| Return on Networth / Equity (%) | 13.83 | 9.19 | 10.37 | 0.51 | 3.81 | |
| Return on Capital Employed (%) | 9.38 | 6.40 | 8.20 | 0.35 | 2.55 | |
| Return on Assets (%) | 6.51 | 4.00 | 5.37 | 0.23 | 1.78 | |
| Total Debt/Equity (X) | 0.60 | 0.68 | 0.54 | 0.81 | 0.76 | |
| Asset Turnover Ratio (%) | 107.03 | 101.72 | 51.41 | 43.53 | 47.95 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.22 | 1.13 | 1.39 | 1.22 | 1.35 | |
| Quick Ratio (X) | 0.71 | 0.65 | 0.75 | 0.41 | 0.55 | |
| Inventory Turnover Ratio (X) | 6.73 | 5.73 | 2.31 | 1.55 | 1.97 | |
| Dividend Payout Ratio (NP) (%) | 4.80 | 8.30 | 7.90 | 0.00 | 17.90 | |
| Dividend Payout Ratio (CP) (%) | 3.23 | 5.09 | 5.12 | 0.00 | 7.14 | |
| Earnings Retention Ratio (%) | 95.20 | 91.70 | 92.10 | 100.00 | 82.10 | |
| Cash Earnings Retention Ratio (%) | 96.77 | 94.91 | 94.88 | 100.00 | 92.86 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 574.53 | 342.62 | 287.01 | 312.72 | 341.38 | |
| EV/Net Operating Revenue (X) | 0.99 | 0.66 | 1.18 | 1.46 | 1.51 | |
| EV/EBITDA (X) | 5.60 | 5.84 | -8.33 | 8.19 | 8.33 | |
| MarketCap/Net Operating Revenue (X) | 0.74 | 0.40 | 0.79 | 0.66 | 0.80 | |
| Retention Ratios (%) | 95.19 | 91.69 | 92.09 | 100.00 | 82.09 | |
| Price/BV (X) | 1.68 | 0.92 | 0.79 | 0.64 | 0.82 | |
| Price/Net Operating Revenue | 0.74 | 0.40 | 0.79 | 0.66 | 0.80 | |
| Earnings Yield | 0.08 | 0.10 | 0.13 | 0.01 | 0.05 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
17.03.2026
16.03.2026
15.03.2026
13.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth